Lotus Pharmaceutical Co., Ltd. AI Stock Analysis
Lotus Pharmaceutical Co., Ltd. (1795) AI Stock Analysis
Lotus Pharmaceutical Co., Ltd.
(TWSE:1795)
The overall score of 56 reflects a company with strong operational profitability and an attractive valuation, but these are overshadowed by significant financial risk and weak technical momentum. The primary concern is the highly leveraged balance sheet, which introduces substantial vulnerability. The stock is also in a clear downtrend across all major moving averages, indicating negative market sentiment. The low P/E ratio provides a potential value opportunity, but it is likely a reflection of the elevated financial risk.
Lotus Pharmaceutical Co., Ltd. (1795) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 37.76B
- Dividend Yield
- 1.64%
- Average Volume (3M)
- 1.09M
- Price to Earnings (P/E)
- 10.8
- Beta (1Y)
- 0.40
- Revenue Growth
- 48.98%
- EPS Growth
- -21.95%
- Country
- TW
- Employees
- 1,099
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Lotus Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Lotus Pharmaceutical Co., Ltd. operates as a pharmaceutical enterprise, specializing in the research, development, production, and sale of generic medicines. Its market presence extends across Taiwan, South Korea, the United States, and other global...
Lotus Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Financial performance is mixed. The income statement is strong (Score 78) with robust revenue growth and high margins. However, the balance sheet is a major concern (Score 35) due to a surge in debt, pushing the debt-to-equity ratio to 2.35. Cash flow is adequate (Score 65) with strong operations but declining free cash flow due to heavy investment. The high leverage significantly drags down the overall financial health score.
Income Statement
78PositiveBalance Sheet
35NegativeCash Flow
65Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.49B | 20.51B | 18.58B | 16.96B | 14.63B | 12.65B |
| Gross Profit | 13.03B | 10.64B | 10.92B | 9.38B | 7.81B | 5.64B |
| EBITDA | 9.44B | 7.44B | 8.21B | 6.87B | 5.26B | 2.93B |
| Net Income | 3.77B | 4.72B | 5.07B | 4.11B | 3.02B | 1.40B |
Balance Sheet | ||||||
| Total Assets | 108.59B | 106.15B | 40.10B | 32.99B | 29.53B | 21.22B |
| Cash, Cash Equivalents and Short-Term Investments | 6.33B | 7.74B | 6.03B | 1.77B | 1.98B | 1.61B |
| Total Debt | 58.45B | 55.93B | 13.67B | 11.58B | 8.92B | 6.39B |
| Total Liabilities | 84.28B | 82.37B | 18.92B | 15.66B | 15.66B | 10.15B |
| Stockholders Equity | 24.31B | 23.78B | 21.18B | 17.33B | 13.87B | 11.07B |
Cash Flow | ||||||
| Free Cash Flow | 2.61B | 3.13B | 4.69B | -1.65B | 650.03M | -1.50B |
| Operating Cash Flow | 4.50B | 7.48B | 6.15B | 1.61B | 3.72B | 119.66M |
| Investing Cash Flow | -13.63B | -12.47B | -2.69B | -3.25B | -4.66B | -1.58B |
| Financing Cash Flow | 11.13B | 6.90B | 714.09M | 1.40B | 1.26B | 1.66B |
Lotus Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
TW:649176Outperform
TW:647260Neutral- TW:179556Neutral
TW:694933Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6491 | 76Outperform | TWD 30.61B | 15.06 | ― | 2.60% | 18.45% | 24.17% |
| TW:6472 | 60Neutral | TWD 51.59B | 32.71 | ― | 2.49% | -5.57% | -62.77% |
| TW:1795 | 56Neutral | TWD 41.49B | 10.79 | ― | 1.64% | 48.98% | -21.95% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6949 | 33Underperform | TWD 58.67B | -159.96 | ― | ― | 7.81% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:1795 | Lotus Pharmaceutical Co., Ltd. | 156.00 | -130.37 | -45.52% | |
| TW:6472 | Bora Pharmaceuticals Co Ltd | 401.00 | -152.21 | -27.51% | |
| TW:6491 | Pegavision Corp. | 385.50 | 63.73 | 19.80% | |
| TW:6949 | PELL Bio-Med Technology Co Ltd | 40.95 | 22.11 | 117.38% | |
| TW:7686 | A-Top Health Biotech Co., Ltd. | 640.00 | 120.00 | 23.08% | |
| TW:7924 | TLC BioSciences Corp | 384.50 | 174.00 | 82.66% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026